Table 2: Methodologies of included studies.

Study Reference Study Design Single Arm or Comparator Combination or Mon Therapy? Country or International Clinical Trial Number Ethical Approval
Fong, 2009 Phase 1non-randomiseddose finding trial Single arm monotherapy UK (Royal Marsden) and Netherlands (Cancer Institute) NCT00516373 Non mentioned
Tutt, 2010 Phase 2Non-randomisedProof of conceptSequential cohort Comparator arm on lower dose (100mg) Monotherapy Multinational - 26 centres across Australia, Germany, Spain, Sweden, UK and USA. NCT00494234 Written informed consentStudy approved by independent ethics committee for each trial centres, done in accordance with good clinical practice guidelines and Declaration of Helsinki
Gelmon, 2011 Phase 2Non-randomisedOpen-label Single arm but can compares results between BRCAm or BRCAwt monotherapy 6 centres across Canada. NCT00679783 Written informed consent. Study protocol approved by health Canada and institutional review boards and the six particiapating sites.
Balmana, 2014 Phase 1`Non-randomisedDose finding trial Single arm Combination therapy (olaparib with cisplatin) Multi centre - country not stated but Balmana works out of University Hospital in Barcelona. NCT00782574 Study carried out in accordance with declaration of Helsinki, good clinical practice and AZ policy on bioethics.
Kaufman, 2015 Phase 2Non-randomised Single arm but can compare different cancer types (ovarian, breast, pancreas, prostate and other) monotherapy Multinational - 13 centres across Israel, Australia, Germany, Spain, Sweden and USA NCT01078662 Written informed consent.Study carried out in accordance with international conference on harmonisation good clinical practice guidelines and declaration of Helsinki and approved by an independent ethics committee or institutional review board at every trial centre.
Van der Noll, 2015 Long-term monotherapy safety study, following a phase 1 combination study Single arm but can compare different cancer types (breast, ovarian and fallopian tube). Monotherapy long-term safety study following a Phase 1 combination study (olaparib with carboplatin and/or paclitaxel). Netherlands Cancer Institute n/a No mention of ethical approval
Robson, 2017 Phase 3RandomisedOpen-label Comparator arm was standard single chemotherapy of physicians choice (capecitabine, eribulin, or vinorelbine) monotherapy International - multi centres across 19 countries (Bulgaria, China, Czech Republic, France, Hungary, Italy, Japan, Korea, Mexico, Peru, Poland, Romania, Russia, Spain, Switzerland, Taiwan, Turkey, UK and USA.. NCT02000622 Protocol approved by ethics written informed consent. review committees at participating institutions